Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.54 |
| ▸ | HTR2B | P41595 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 7/20 | 0.46 |
| ▸ | MASP2 | O00187 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14542806 | 0.86 | HTR2C (0.52) | HTR2CHTR2BKDM4EF2MASP2 | |
| SCHEMBL6606024 | 0.86 | F2 (0.61) | HTR2CHTR2BF2MASP2 | |
| SCHEMBL26397738 | 0.82 | HTR2C (0.59) | HTR2CHTR2BKDM4EF2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL23452425 | 0.82 | HTR2C (0.50) | HTR2CHTR2BKDM4EF2MASP2 | |
| Hydrochloric Acid SCHEMBL23452421 | 0.82 | HTR2C (0.50) | HTR2CHTR2BKDM4EF2MASP2 | |
| SCHEMBL13238639 | 0.80 | HTR2C (0.51) | HTR2CHTR2BKDM4EF2MASP2 | |
| SCHEMBL8809131 | 0.80 | HTR2C (0.64) | HTR2CHTR2BKDM4EF2MASP2 | |
| Hydrochloric Acid SCHEMBL5900833 | 0.79 | HTR2C (0.62) | HTR2CHTR2BKDM4EF2MASP2 | |
| Hydrochloric Acid SCHEMBL5900838 | 0.79 | HTR2C (0.62) | HTR2CHTR2BKDM4EF2MASP2 | |
| SCHEMBL27441820 | 0.78 | MASP2 (0.44) | F2MASP2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661418-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661418-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | HTR2C 3776/4885HTR2B 3978/4885KDM4E 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.